Xenoscience

Phoenix, Arizona 85013

2 studies enrolling now · 21 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Cognitive Decline, Cognitive Dysfunction, Dementia, Alzheimer Type, Developmental and/or Epileptic Encephalopathies, Early Alzheimer's Disease, Early Alzheimers Disease, Epilepsies, Partial, Focal Epilepsy, Focal Onset Seizures, Mild Cognitive Impairment

Studies at this site

• A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures — Recruiting now
• An Open-label Study of XEN1101 in Epilepsy — Enrolling by invitation
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD — Running, not enrolling
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures — Completed
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease — Running, not enrolling
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Running, not enrolling
• Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type — Completed
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis — Completed
• Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies — Completed
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy — NO_LONGER_AVAILABLE
• A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease — Completed
• An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type — Completed
• Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures — Stopped early